Journal ArticleDOI
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis
Elliot M. Frohman,Eva Havrdova,Fred D. Lublin,Frederik Barkhof,A. Achiron,A. Achiron,M. K. Sharief,Olaf Stüve,Michael K. Racke,Lawrence Steinman,Howard L. Weiner,Michael J. Olek,Robert Zivadinov,John R. Corboy,Cedric S. Raine,Gary Cutter,J. R. Richert,Massimo Filippi +17 more
TLDR
The natural history of multiple sclerosis—a geographically based study, 2: predictive value of the early clinical course, 3: multivariate analysis of predictive factors and models of outcome, and 4: Prediction of outcome in multiple sclerosis based on multivariate models.Abstract:
1aforearlymultiplesclerosis:CHAMPStrialsubgroup analyses. Ann Neurol. 2002;51:481-490. 42. Hadjimichael O, Vollmer TL. Adherence to injection therapy in multiple sclerosis: patients survey. Neurology. 1999;52:A549. 43. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 1996;47:889-894. 44. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004; 62:2031-2037. 45. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis: Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998;50:1266-1272. 46. Rice G. The significance of neutralizing antibodies inpatientswithmultiplesclerosis treatedwith interferon beta. Arch Neurol. 2001;58:1297-1298. 47. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis—a geographically based study, 2: predictive value of the early clinical course. Brain. 1989;112:1419-1428. 48. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis—a geographically based study, 3: multivariate analysis of predictive factors and models of outcome. Brain. 1991;114:1045-1056. 49. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol. 1994;241: 597-604. 50. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103:281-300.read more
Citations
More filters
Journal ArticleDOI
Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up
Michael C. Brodsky,Michael C. Brodsky,Sarkis Nazarian,Silvia Orengo-Nania,George J. Hutton,Edward G. Buckley,E. Wayne Massey,M. Tariq Bhatti,M. Tariq Bhatti,Melvin Greer,James Goodwin,Michael Wall,Peter J. Savino,Thomas Leist,Neil R. Miller,David N. Irani,Jonathan D. Trobe,Wayne T. Cornblath,David I. Kaufman,Eric R. Eggenberger,Mark J. Kupersmith,William T. Shults,Leslie McAllister,Steve Hamilton,Roy W. Beck,Mariya Dontchev,Robin L. Gal,Craig Kollman,John L. Keltner,Craig H. Smith +29 more
TL;DR: The presence of brain MRI abnormalities at the time of an optic neuritis attack is a strong predictor of the 15-year risk of MS.
Journal ArticleDOI
An approach to the diagnosis of acute transverse myelitis
Anu Jacob,Brian G. Weinshenker +1 more
TL;DR: Clinical, immunological, and radiological findings of non-compressive myelopathies are reviewed, as are how these findings can be used to distinguish between demyelinating, infectious, other inflammatory, vascular, neoplastic, and paraneoplastic etiologies.
Journal Article
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
TL;DR: Although no treatment benefit was seen on the time to confirmed progression of disability, relapse- and MRI- related outcomes showed significant benefit with both dosing regimens tested, a result consistent with the outcomes of earlier clinical trials.
Journal ArticleDOI
Optical coherence tomography in multiple sclerosis.
Elliot M. Frohman,Fiona Costello,Robert Zivadinov,Olaf Stüve,Olaf Stüve,Amy Conger,Heather Winslow,Anand Trip,Teresa C. Frohman,Laura J. Balcer +9 more
TL;DR: This review considers the usefulness of optical imaging of the retina as a biomarker for neurodegeneration in multiple-sclerosis and the coupling of quantifiable measures of visual function with ocular imaging techniques, such as optical coherence tomography.
Journal ArticleDOI
Clinical predictors of early second event in patients with clinically isolated syndrome
TL;DR: Non-white race/ethnicity, younger age, and a lower number of FS affected by the IDE are associated with a substantially increased hazard ratio for a second demyelinating event within 1 year.
References
More filters
Journal ArticleDOI
Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS)
TL;DR: A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9).
Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
TL;DR: The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
Journal ArticleDOI
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Journal ArticleDOI
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
D. W. Paty,David Kb Li +1 more
TL;DR: The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.
Journal ArticleDOI
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
TL;DR: In this paper, a double-blind, placebo-controlled study was conducted to investigate the effects of subcutaneous interferon β-1a on relapsing/remitting MS.